http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A 3-prismatic-revolute-spherical compliant parallel platform for optoelectronic packaging
Hongwei Xu,Haibo Zhou,Shuaixia Tan,Zhiping Kong,Ji-An Duan 대한기계학회 2022 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.36 No.6
To align the optical channels of optoelectronic appliances, a 3-prismaticrevolute-spherical (3-PRS) compliant parallel platform (CPP) is proposed in this work. The platform has special large stroke compliant joints. Attention is paid to the establishment of the inverse kinematics model and the analysis of the parasitic motion (PM) of the platform. A prototype of the platform is also presented, and its accuracy is experimentally evaluated. Besides, the platform is employed as a 3 degree-of-freedom (DOF) platform for optoelectronic packaging. Furthermore, the closed-loop control strategy requires merely one optical power meter to avoid the use of complex multiple DOF detection devices. In this respect, the influence of the precision of inverse kinematics solution on the optoelectronic packaging is reduced. Moreover, a compensation rule is employed to minimize the effect of PM on the motion accuracy of the platform. The results show that the proposed 3-PRS CPP is highly efficient for optoelectronic packaging.
Nan Shi,Hongwei Xu,Kaiyuan Guo,Chunyu Kang,Wei Zhang,Yingying Zhang,Liping Zhang,Jianxin Tan 한국화학공학회 2017 Korean Journal of Chemical Engineering Vol.34 No.8
Partitioning of microbial transglutaminase (MTG) from Amycolatopsis sp. in the polyethylene glycol (PEG)/salt-based ATPS was investigated for the first time. The key parameters such as the molecular weight of PEG (PEG 600-6000), the type and concentration of phase-forming salt (ammonium sulfate or phosphates), the pH of system (pH 5.0-8.5), and the concentration of neutral salt (0-6% NaCl, w/w) were determined. The partition coefficient of the enzyme was not linear with PEG molecular weight; PEG1000 gave better yield than others. The concentration of PEG1000, ammonium sulfate and NaCl, and the system pH showed effects with different extents on specific activity (SA) and yield of the enzyme. In the ATPS of 26% w/w PEG 1000 and 19% w/w ammonium sulfate in the presence of 5% w/w NaCl and at pH 6.0, MTG was partitioned into the PEG-rich phase with a maximum yield of 86.51% and SA was increased to 0.83. The results of SDS-PAGE showed the MTG produced by the test strain differed from the enzymes reported before. Thus, this study proves that ATPS can be used as a preliminary step for partial purification of MTG from Amycolatopsis sp. fermentation broth.
Challenges for commercializing perovskite solar cells
Rong, Yaoguang,Hu, Yue,Mei, Anyi,Tan, Hairen,Saidaminov, Makhsud I.,Seok, Sang Il,McGehee, Michael D.,Sargent, Edward H.,Han, Hongwei American Association for the Advancement of Scienc 2018 Science Vol.361 No.6408
<P>Perovskite solar cells (PSCs) have witnessed rapidly rising power conversion efficiencies, together with advances in stability and upscaling. Despite these advances, their limited stability and need to prove upscaling remain crucial hurdles on the path to commercialization. We summarize recent advances toward commercially viable PSCs and discuss challenges that remain. We expound the development of standardized protocols to distinguish intrinsic and extrinsic degradation factors in perovskites. We review accelerated aging tests in both cells and modules and discuss the prediction of lifetimes on the basis of degradation kinetics. Mature photovoltaic solutions, which have demonstrated excellent long-term stability in field applications, offer the perovskite community valuable insights into clearing the hurdles to commercialization.</P>
Liu Yajun,Li Chenyao,Liu Hongwei,Tan Shutao 대한약학회 2024 Archives of Pharmacal Research Vol.47 No.5
The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical trials for cancer therapy. However, owing to disadvantages such as organ toxicity and drug resistance, only one HSP90 inhibitor has been approved for use in clinical settings. In recent years, HSP90 inhibitors used in combination with other anti-cancer therapies have shown remarkable potential in the treatment of cancer. HSP90 inhibitors work synergistically with various anti-cancer therapies, including chemotherapy, targeted therapy, radiation therapy and immunotherapy. HSP90 inhibitors can improve the pharmacological effects of the above-mentioned therapies and reduce treatment resistance. This review provides an overview of the use of combination therapy with HSP90 inhibitors and other anti-cancer therapies in clinical and preclinical studies reported in the past decade and summarises design strategies and prospects for these combination therapies. Altogether, this review provides a theoretical basis for further research and application of these combination therapies in the treatment of cancer.